HUP0402364A2 - Gyorsan oldódó, nagy koncentrációjú ribavirinkészítmények - Google Patents

Gyorsan oldódó, nagy koncentrációjú ribavirinkészítmények

Info

Publication number
HUP0402364A2
HUP0402364A2 HU0402364A HUP0402364A HUP0402364A2 HU P0402364 A2 HUP0402364 A2 HU P0402364A2 HU 0402364 A HU0402364 A HU 0402364A HU P0402364 A HUP0402364 A HU P0402364A HU P0402364 A2 HUP0402364 A2 HU P0402364A2
Authority
HU
Hungary
Prior art keywords
ribavirin
high loading
mixing
preparation
produce
Prior art date
Application number
HU0402364A
Other languages
English (en)
Inventor
Amol Singh Matharu
Mahendra R. Patel
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of HUP0402364A2 publication Critical patent/HUP0402364A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

A találmány tárgya gyorsan oldódó, nagy koncentrációjúribavirinkészítmény, amely lényegében mentes a ribavirin polimorfformáitól, és olyan eljárással van előállítva, hogy a) a ríbavirintlegalább egy szétesést elősegítő szerrel és/vagy legalább egytöltőanyaggal keverik össze, hogy homogén keveréket állítsanak elő; b)a keveréket víz jelenlétében granulátummá granulálják; c) agranulátumot megszárítják; és d) legalább egy szétesést elősegítőszert és/vagy legalább egy lubrikánst összekevernek a granulátummal,hogy ríbavirinkészítményt állítsanak elő. A ribavirinkészítményt azjellemzi, hogy legalább 80 tömeg% ribavirint tartalmaz a készítményteljes tömegére számítva. A találmány szerinti nedves granulációseljárással előállított ribavirinkészítmények szabadon folynak, ésmegfelelő a tömbsűrűségük a kapszulázáshoz. A ribavirinkészítményeklényegében mentesek a ribavirin polimorf formáitól, vagyis infravörösspektrofotometriával nem mutathatók ki polimorf változások jelei aribavirinben. Ó
HU0402364A 2001-11-02 2002-10-31 Gyorsan oldódó, nagy koncentrációjú ribavirinkészítmények HUP0402364A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33685301P 2001-11-02 2001-11-02
PCT/US2002/034899 WO2003039517A1 (en) 2001-11-02 2002-10-31 Process for preparing quick dissolving, high loading ribavirin compositions

Publications (1)

Publication Number Publication Date
HUP0402364A2 true HUP0402364A2 (hu) 2005-02-28

Family

ID=23317956

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402364A HUP0402364A2 (hu) 2001-11-02 2002-10-31 Gyorsan oldódó, nagy koncentrációjú ribavirinkészítmények

Country Status (16)

Country Link
US (1) US20030104050A1 (hu)
EP (1) EP1443911A1 (hu)
JP (1) JP2005511587A (hu)
KR (1) KR20050042035A (hu)
CN (1) CN1585631A (hu)
AU (1) AU2002350082B9 (hu)
BR (1) BR0213861A (hu)
CA (1) CA2465159A1 (hu)
HR (1) HRP20040384A2 (hu)
HU (1) HUP0402364A2 (hu)
IL (1) IL161697A0 (hu)
MX (1) MXPA04004181A (hu)
NO (1) NO20042143L (hu)
PL (1) PL368550A1 (hu)
RU (1) RU2004116821A (hu)
WO (1) WO2003039517A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
ES2523148T3 (es) * 2004-05-24 2014-11-21 Takeda Nycomed As Material en forma de partículas que comprende un compuesto que contiene calcio y un alcohol de azúcar
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US7723310B2 (en) * 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
US20060110479A1 (en) * 2004-11-24 2006-05-25 Mitra Shankar K Natural composition for curing hepatitis-B, methods for making the same and pharmaceutical formulations thereof
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
EP2101739A2 (en) * 2006-12-21 2009-09-23 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
US8202996B2 (en) * 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2010062996A2 (en) * 2008-11-28 2010-06-03 Adamas Pharmaceuticals, Inc. Ribavirin composition
EP2295037A1 (en) 2009-09-11 2011-03-16 Ratiopharm GmbH Pharmaceutical formulation containing Ribavirin
US20130190263A1 (en) * 2010-06-08 2013-07-25 Laboratorio De Diagnostico Gam, S.A. Oral veterinarian composition for salmonids comprising 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide and use thereof in the treatment of infectious anemia in salmonids
US20190076467A1 (en) * 2015-06-09 2019-03-14 Commonwealth Scientific And Industrial Research Organisation Antiviral conjugates of polyanionic polymer and antiviral drug
CN106806345B (zh) * 2015-11-27 2020-10-13 北京科信必成医药科技发展有限公司 一种利巴韦林掩味颗粒及其制备方法
CN108464972A (zh) * 2018-07-02 2018-08-31 福州大学 一种含有斯诺普利的抗肺动脉高压口服片剂及其制备方法
CA3194665A1 (en) 2020-10-05 2022-04-14 Jia-Ning Xiang Modified release compositions of a gamma-hydroxybutyric acid derivative
CN113304114B (zh) * 2021-06-08 2022-06-10 药大制药有限公司 一种利巴韦林颗粒及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3277520A (en) * 1963-06-18 1966-10-11 Fuji Denki Kogyo Kabushiki Kai Method and apparatus for making spherical granules
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3976545A (en) * 1973-03-12 1976-08-24 Icn Pharmaceuticals, Inc. 1,2,4-Triazol E-3-carboxamides as antiviral agents
US3948885A (en) * 1973-03-19 1976-04-06 Icn Pharmaceuticals, Inc. 5-Hydroxyl-1,2,3-triazole-4-carboxamide nucleoside
US4138547A (en) * 1977-12-22 1979-02-06 Icn Pharmaceuticals, Inc. Process for preparing 1,2,4-triazole nucleosides
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5405837A (en) * 1993-05-18 1995-04-11 Indiana University Foundation Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
AU7473096A (en) * 1995-11-02 1997-05-22 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) * 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
ES2195970T3 (es) * 1996-10-16 2003-12-16 Ribapharm Inc L-ribavirina y usos de la misma.
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
JP2001526234A (ja) * 1997-12-22 2001-12-18 シェーリング コーポレイション 経口投与が可能な固形リバビリン投薬の形態およびそれらの製造プロセス
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets

Also Published As

Publication number Publication date
CN1585631A (zh) 2005-02-23
IL161697A0 (en) 2004-09-27
PL368550A1 (en) 2005-04-04
AU2002350082B2 (en) 2006-07-20
CA2465159A1 (en) 2003-05-15
KR20050042035A (ko) 2005-05-04
AU2002350082B9 (en) 2006-08-31
US20030104050A1 (en) 2003-06-05
JP2005511587A (ja) 2005-04-28
RU2004116821A (ru) 2005-04-20
MXPA04004181A (es) 2005-01-25
WO2003039517A1 (en) 2003-05-15
HRP20040384A2 (en) 2005-08-31
BR0213861A (pt) 2004-12-21
EP1443911A1 (en) 2004-08-11
NO20042143L (no) 2004-05-25

Similar Documents

Publication Publication Date Title
HUP0402364A2 (hu) Gyorsan oldódó, nagy koncentrációjú ribavirinkészítmények
HUP9903992A2 (hu) Tömörített granulátum, eljárás az előállítására és szétesést elősegítő szerként történő alkalmazása
HUP9903991A2 (hu) Tömörített granulátum, eljárás az előállítására és szétesést elősegítő szerként történő alkalmazása
BG108497A (en) Solid-phase nucleophilic fluorination
DK1001748T3 (da) Fremgangsmåde til fremstilling af et granulat, som er egnet til fremstilling af i munden oplöselige tabletter, som kan sönderdeles hurtigt
NO20053115D0 (no) Fremgangsmate for fremstilling av 2'-forgrenede nukleosider.
CA2463947A1 (en) Montelukast granule formulation
BR0314340A (pt) Formulações que compreendem granulados solúveis em água
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
HUP0401238A2 (hu) Amorf nelfinavir-mezilátot tartalmazó gyógyászati adagolási forma és eljárás az előállítására
MY136524A (en) New solid pharmaceutical formulations comprising telmisartan and preparation thereof
MXPA04003027A (es) Metodos para granulacion humeda de azitromicina.
NO20055814L (no) Aluminasilikatblanding for fremstilling av ildfaste, hoysterke granuler, slike granuler og fremgangsmate for fremstilling av slike
TR200200716T2 (tr) Ketiyapin granülleri
ATE424814T1 (de) Schnell zerfallende im mund dispergierbare zusammensetzung mit nicht-filamentösen mitverarbeiteten polyol-teilchen und verkieselter mikrokristalliner cellulose
DK1474995T3 (da) Fremgangsmåde til fremstilling af tyggegummigranulater, et gummisammensætningsekstruder- og granuleringssystem og et tyggegummiprodukt
EA201001537A1 (ru) Гранулированная агрохимическая композиция и способы её получения
NO20032737L (no) Fast termoformbar farmasöytisk sammensetning for den kontrollerte frigivelse av ivabradin
HUP0104341A2 (hu) Granulátum, valamint eljárás és berendezés annak előállítására
DK1441700T3 (da) Fremgangsmåde til fremstilling af en farmaceutisk sammensætning omfattende 5-aminosalicylsyre til anvendelse ved behandling af ulcerativ colitis og Crohn's sygdom
ES2120514T3 (es) Formulacion solida para la proteccion de cultivos.
TNSN03065A1 (en) BIOPESTICIDE COMPOSITIONS
RS20050933A (en) Process for the preparation of nonpeptide substit uted spirobenzoazepine derivatives
ZA200405376B (en) Granulated product and process to prepare the same.
ATE271378T1 (de) Neue galenische dispergierbare und lösliche paracetamol-zubereitung, methode zu deren herstellung und deren anwendungen

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees